cn is the China-region web presence (cn.ausperbio.com) of AusperBio Therapeutics (Hangzhou Ausper Bio / 杭州浩博医药有限公司), a Phase II clinical-stage biopharmaceutical company dedicated to transforming HBV treatment toward a functional cure and advancing oligonucleotide therapeutics. AusperBio leverages its proprietary Med-Oligo ASO platform with targeted delivery technologies to apply antisense oligonucleotide (ASO) therapeutics across viral infections, metabolic conditions, genetic disorders, and immune diseases; its lead candidate AHB-137 is an unconjugated ASO advancing through Phase II/III trials for chronic hepatitis B. Surfaced as a portfolio company of Qiming Venture Partners and added to the API Evangelist network as a stub; the company publishes a marketing website but no public developer or API surface.
cn is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Biopharmaceutical, and Clinical Stage.
cn’s developer surface includes engineering blog and 2 more developer resources.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Show this score on your site.
It updates itself when the score changes. Paste this where you link to your API docs:
<a href="https://apis.io/providers/cn/"><img src="https://apis.io/badge/cn/card.svg" alt="cn on APIs.io — Kin Score by API Evangelist"></a>
Other styles, a README pill and a shields.io endpoint are on the badge page.
Raise your score.
Agent readiness — checks not met, largest first (exact, from this profile):
Machine-Readable Auth+10 pts — a served openid-configuration/oauth-authorization-server carrying `issuer` (served), else the securitySchemes class in the provider OpenAPIs — bound (mutualTLS, DPoP, Signature) > negotiable (oauth2 authorizationCode/clientCredentials, openIdConnect) > bearer (http bearer, apiKey)
Idempotency+9 pts — OpenAPI mutating operations declare an idempotency key — a header, a request-body property, or a named de-duplication token whose own description says so (verified); else common[].type matches /idempoten/i (documented)
Stable Error Semantics+8 pts — OpenAPI $refs a shared error schema across 4xx/5xx responses (verified), else common[].type includes ErrorCatalog / ErrorCodes / DeclineCodes
13 more unmet checks in the Agent Readiness table above.
Kin Score — facets with the most composite points still available (weight × headroom):
aid: cn
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source:
- security
generated: '2026-11-06'
method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/cn.png
name: cn
description: cn is the China-region web presence (cn.ausperbio.com) of AusperBio Therapeutics (Hangzhou Ausper Bio / 杭州浩博医药有限公司),
a Phase II clinical-stage biopharmaceutical company dedicated to transforming HBV treatment toward a functional cure and
advancing oligonucleotide therapeutics. AusperBio leverages its proprietary Med-Oligo ASO platform with targeted delivery
technologies to apply antisense oligonucleotide (ASO) therapeutics across viral infections, metabolic conditions, genetic
disorders, and immune diseases; its lead candidate AHB-137 is an unconjugated ASO advancing through Phase II/III trials
for chronic hepatitis B. Surfaced as a portfolio company of Qiming Venture Partners and added to the API Evangelist network
as a stub; the company publishes a marketing website but no public developer or API surface.
url: https://raw.githubusercontent.com/api-evangelist/cn/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- qiming
x-tier: stub
x-tier-reason: portfolio-lead
x-enrichment: Slug "cn" is a mis-parse of the cn.ausperbio.com regional subdomain; real entity is AusperBio Therapeutics (www.ausperbio.com).
No developer/API surface exists (marketing SPA only; cms.ausperbio.com is an internal headless CMS, not a public API). No
OpenAPI, SDKs, MCP, webhooks, or docs to enrich. Domain-security probed; well-known paths all catch-all 200 (no real discovery
documents).
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-10-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Biopharmaceutical
- Clinical Stage
- Oligonucleotide Therapeutics
- Hepatitis B
- Drug Development
tags_raw:
- Company
- Biotechnology
- Pharmaceuticals
- Biopharmaceutical
- Clinical-Stage
- Oligonucleotide Therapeutics
- Hepatitis B
- Drug Development
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- url: https://www.ausperbio.com/blog/
type: Blog
- type: DomainSecurity
url: security/cn-domain-security.yml
- type: Website
url: https://www.ausperbio.com
Calls without X-API-Key need no key. Calls with it need a paid plan — get a key.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.